The global glycated albumin assay market, valued at US$0.1 billion in 2022, is forecasted to grow at a robust CAGR of 8.9%, reaching US$0.2 billion in 2023 and an impressive US$0.3 billion by 2028. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
Market growth is driven by the increased focus of the government on disease diagnosis, the high prevalence of diabetes, and increasing initiatives to spread awareness of diabetes diagnosis.
Driver: Rising prevalence of diabetes
Diabetes is a common chronic metabolic disease that occurs due to insulin dysfunction in the pancreas. Hyperglycemia, also called raised blood glucose or raised blood sugar, is a common effect of uncontrolled diabetes. Diabetes can cause serious damage to bodily functions, especially nerves and blood vessels. The increasing prevalence of diabetes has a positive impact on the glycated albumin assay industry.
Restraint: Unfavorable reimbursement scenario
Inadequate reimbursement is a major factor restraining the growth of the glycated albumin assay diagnostics market. Most diagnostic companies face a major challenge in commercializing their tests is getting approval and reimbursement for the diagnostic product. most diagnostic companies face in commercializing their tests is getting Medicare and private health insurers to pay for them. This is important not only to help the decision-making process of physicians within the practice of evidence-based medicine but also to achieve regulatory approvals and reimbursements for the tests. The reimbursement levels for diagnostics set by the Centers for Medicare and Medicaid Services (CMS) does not adequately reflect their actual cost or clinical value. This decline and additional budgetary concerns among healthcare systems will be a major obstacle to implementing novel diagnostic techniques in clinical laboratories.
Opportunity: Rising investments in healthcare and life sciences research
The market is anticipated to have considerable growth possibilities in emerging markets like India, South Korea, Brazil, and Mexico. This is explained by the high disease prevalence, substantial patient population, enhanced healthcare system, rising disposable income, and expanding medical tourism in these nations. The Asia Pacific region has become a flexible and business-friendly hub because to fewer onerous rules and data requirements, in addition to the aforementioned considerations.
Challenge: Changing regulatory landscape
Regulatory and legal requirements applied to diagnostics (including glycated albumin assay) in the US and European countries are becoming more stringent. Under US federal regulations, device manufacturers must submit a 510(k) application for any further modifications to a device, which is a major challenge in the growth of this market.
IVD devices must comply with Annex 1 of the directive’s essential requirements, and products must be CE-marked to be legally marketed in the EU. New regulations are expected to replace earlier EU directives and add stringent requirements for the CE Marking of new and existing devices. Su.ch changes in the regulatory landscape can prove challenging to the growth of the glycated albumin assay industry.
In 2022, type 2 diabetes segment accounted for the largest share of the glycated albumin assay industry, by application
The glycated albumin assay market is segmented into prediabetes, type 1 diabetes, and type 2 diabetes. The type 2 diabetes segment accounted for the largest share of the market in 2022, mainly due to the rising geriatric population & type 2 diabetes prevalence.
In 2022, hospitals and diabetes care centers segment dominated the glycated albumin assay industry, by end user
The glycated albumin assay market is segmented into hospitals and diabetes care centers, diagnostic laboratories and other end users based on end user. In 2022, the hospitals and diabetes care centers segment accounted for the largest share. Laboratories within these segments perform glycated albumin assays to identify or diagnose diabetes and determine appropriate treatments. These urine and blood samples are tested for the physiological parameters related to diabetes. As compared to reference laboratories, hospitals offer quicker test results and are more accessible. This is expected to support the growth of this end user segment.
North America is the largest regional market for glycated albumin assay industry
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are the five main geographic segments of the worldwide glycated albumin assay market. North America held the biggest market share for glycated albumin assays globally in 2022. The North American market’s growth can be attributed to the increase prevalence of lifestyle diseases such as diabetes and supportive government initiatives regarding effective diabetes management. Healthcare coverage expansions by Medicaid, Medicare, and private health insurance companies in the region are also expected to play a significant role in fueling the market growth. Other factors supporting market growth include the growing geriatric population, the implementation of favorable government initiatives, and technologically advanced assays.
Source:https://www.marketsandmarkets.com/Market-Reports/glycated-albumin-assay-market-265553363.html